Gonadorelin 50

Therapeutic indications:

The drug is used to regulate reproductive function:

• in cattle: for the induction of follicular ovulation in luteinizing hormone deficiency, synchronization of ovulation, stimulation of ovarian function in the postpartum period, as well as for follicular ovarian cysts;
• in pigs: for the synchronization of ovulation and an increase in fertilization rate.

Pharmacotherapeutic group:

Estrogens, gestagens; their homologues and antagonists. Gonadoliberin.

Dosage form description

Solution for intramuscular and subcutaneous administration. In appearance, the drug is a transparent, colorless solution.

Colorless glass vials of 10 ml.

Composition of the veterinary drug:

1 ml of the drug contains 50 mcg of gonadorelin (as gonadorelin acetate) as the active substance.

Pharmacological activity:

Gonadorelin, the active substance of the drug, is a synthetic peptide, an analogue of natural gonadoliberin. Its pharmacological action is completely identical to that of natural gonadoliberin, meaning that gonadorelin induces the formation and release of follicle-stimulating and luteinizing hormones from the adenohypophysis, growth and maturation of follicles, synthesis and secretion of estrogens, stimulates ovulation, and controls the function of the corpus luteum of the ovaries.

Following a single intramuscular administration, gonadorelin is rapidly absorbed from the injection site and reaches its maximum concentration in blood serum within 15 minutes. The bioavailability of gonadorelin is about 89%. The highest concentration of the hormone is found in the liver, kidneys, and lungs. Within 8–24 hours, gonadorelin binds to blood proteins up to 73%. Gonadorelin is rapidly excreted in milk, urine, and feces as inactive metabolites. In terms of its effect on the body, the drug does not exhibit sensitizing, embryotoxic, or teratogenic effects.

Dosage:

The drug is administered intramuscularly and subcutaneously in the following doses. Cattle (cows, heifers) intramuscularly (into the neck region or the inner surface of the thigh):

• for the induction of ovulation after estrus synchronization — 1–2 ml of the drug per administration to one animal;
• for follicle persistence and ovulation delay — 2 ml of the drug per administration to one animal 2 hours before artificial insemination and 2 hours after it;
• for stimulation of ovarian function in the postpartum period — 1 ml of the drug per administration to one animal on the 12th day after calving;
• for the treatment of follicular ovarian cysts — 2–3 ml of the drug per administration to one animal once.

For pigs, to synchronize ovulation and increase fertilization rate, intramuscularly or subcutaneously in doses:

• to sows — 0.5–1 ml of the drug per administration to one animal;
• to replacement gilts — 1–1.5 ml of the drug per administration to one animal.

Contraindications:

The drug is contraindicated in animals with increased individual sensitivity to its components.

Overdose:

Symptoms of overdose upon application of the drug in animals have not been identified.

Pregnancy and lactation:

It is prohibited to use the drug during pregnancy after a two-week period.

Special indications:

No specific effects of the drug's action upon its first use or discontinuation have been identified. It is necessary to avoid skipping a scheduled administration of the drug to animals, as this may lead to a decrease in therapeutic efficacy. If a dose is missed, the course of administration must be resumed in accordance with the prescribed dose and treatment regimen. It is prohibited to use the drug in weakened animals, animals with below-average body condition, as well as those that have not reached sexual maturity.

Side effects and individual intolerance:

Adverse reactions and complications when using the drug in accordance with this instruction are generally not observed.

Interaction with other veterinary medicinal products:

The drug is not recommended to be used simultaneously with other hormonal preparations. A synergistic effect when using the drug is observed from combined therapy with follicle-stimulating hormone.

Withdrawal period:

Products obtained from animals to which the drug was administered are allowed to be used for food purposes without restrictions.

Shelf-life:

2 years from the manufacturing date. Use of the drug after the expiration date is prohibited.

Storage conditions:

In a place protected from light at a temperature from 2 °C to 25 °C. The drug should be stored in a place inaccessible to children. After the first opening of the vial – 28 days subject to storage conditions.